Significados de oral etoposide en inglés

Three of five CMML patients who failed treatment with hydroxyurea experienced major hematological responses with oral etoposide.

We conclude that low-dose oral etoposide has remitting activity in MDS and is an effective treatment alternative for patients with CMML.

This phase I trial was carried out to determine the recommended duration of oral etoposide in combination with a fixed dose of carboplatin.

Intravenous and oral etoposide (VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma.

Oral etoposide has limited activity as third- or fourth-line agent and produces significant hematologic toxicity in patients with heavily pretreated metastatic breast cancer.